EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Tomono Kawase, Hiroshi Imamura, Ryohei Kawabata, Jin Matsuyama, Kazuhiro Nishikawa, Kazuhiro Yanagihara, Kazuyoshi Yamamoto, Noriyuki Hoki, Junji Kawada, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa und 2 weitere

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-023-02437-4 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Tomono Kawase und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Toyonaka Municipal Hospital, 4-14-1 Shibahara-cho, Toyonaka-city, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Neutropenia. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although there is insufficient evidence for the treatment of older patients with advanced gastric cancer, fluorouracil combined with platinum chemotherapy has been recognized as a standard first-line treatment for such populations in Japan despite the lack of efficacy and toxicity data. METHODS: Patients aged 75 years or older with advanced gastric cancer were enrolled. S-1 plus docetaxel (docetaxel: 40 mg/m2, day 1; S-1: 80 mg/m2, days 1-14; q21 days) was repeated every 3 weeks. The primary endpoint was overall response rate. Secondary endpoints were safety, progression-free survival, time to treatment failure, and overall survival. The sample size was calculated as 30 under the hypothesis of an expected response rate of 40% and a threshold response rate of 20%, at a power of 90% and a two-sided alpha value of 5%. RESULTS: From February 2010 to January 2015, 31 patients were enrolled and assessed for efficacy and toxicity. The response rate was 45.2% (95% CI 27.3%-64.0%; p = 0.001) and it exceeded the expected response rate set at 40%. Median progression-free survival was 5.8 months, the 1-year survival rate was 58.1%, and the median survival time was 16.1 months. The major grade 3/4 adverse events were neutropenia (58%), febrile neutropenia (13%), anemia (10%), anorexia (10%), and fatigue (6%). CONCLUSIONS: These findings indicate that S-1 plus docetaxel as first-line treatment for older patients is feasible and that it has promising efficacy against advanced gastric cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsNeutropeniaHumansDocetaxelFluorouracilProgression-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsTreatment Outcome

Stichwörter der Autor:innen

DocetaxelGastric cancerOlder patientsS-1

Substanzen

DocetaxelFluorouracil

Autor:innen und Institutionen

  • Department of Surgery, Toyonaka Municipal Hospital, 4-14-1 Shibahara-cho, Toyonaka-city, Japan.
  • Department of Surgery, Toyonaka Municipal Hospital, 4-14-1 Shibahara-cho, Toyonaka-city, Japan. imamurahiroshisakai@yahoo.co.jp.
  • Department of Surgery, Sakai City Medical Center, 1-1-1 Ebaraji-cho, Nishi-ku, Sakai-city, Japan.
  • Department of Surgery, Osaka Rosai Hospital, 1179-3 Nakasone-cho, Kita-ku, Sakai-city, Japan.
  • Department of Gastroenterological Surgery, Higashiosaka City Medical Center, 3-4-5 Nishiiwata, Higashiosaka-city, Japan.
  • Department of Medical Oncology, Kansai Electric Power Hospital, 2-1-7 Fukushima, Fukushima-ku, Osaka-city, Japan.

Zitieren

APA

Kawase, T., Imamura, H., Kawabata, R., Matsuyama, J., Nishikawa, K., Yanagihara, K., Yamamoto, K., Hoki, N., Kawada, J., Kawakami, H., Sakai, D., Kurokawa, Y., Shimokawa, T., & Satoh, T. (2024). Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902). International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-023-02437-4

Vancouver

Kawase T, Imamura H, Kawabata R, Matsuyama J, Nishikawa K, Yanagihara K, et al. Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902). International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-023-02437-4

BibTeX
@article{Kawase2024,
  author = {Kawase, Tomono and Imamura, Hiroshi and Kawabata, Ryohei and Matsuyama, Jin and Nishikawa, Kazuhiro and Yanagihara, Kazuhiro and Yamamoto, Kazuyoshi and Hoki, Noriyuki and Kawada, Junji and Kawakami, Hisato and Sakai, Daisuke and Kurokawa, Yukinori and Shimokawa, Toshio and Satoh, Taroh},
  title = {Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-023-02437-4}
}
Kostenlos starten →